This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion
by Zacks Equity Research
Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.
Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
by Zacks Equity Research
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
Is a Surprise in the Cards for Novartis in Q2 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.
Novartis to Spin-Off Alcon as Separate Trading Company
by Zacks Equity Research
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Novartis Announces Positive Data on CAR-T Therapy, Kymriah
by Zacks Equity Research
Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
by Zacks Equity Research
Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
by Zacks Equity Research
Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
by Zacks Equity Research
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Intel Security Flaw, Spark Therapeutics, & Tech Buyout Rumors
by Ryan McQueeney
On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including the major security flaw found in Intel processors, a cure for a rare blindness discovered by a young biotech firm, and several huge tech industry M&A rumors.
Spark Therapeutics Hopes to Cure a Rare Blindness for $850,000 a Pop
by Madeleine Johnson
Small biotech firm Spark Therapeutics (ONCE) recently announced a new gene therapy that is designed to treat a rare, inherited retinal disease that can cause blindness. Approved by the FDA, Luxturna costs $425,000 per eye, or $850,000 for both
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
by Zacks Equity Research
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Why Spark Therapeutics (ONCE) Might Surprise This Earnings Season
by Zacks Equity Research
Spark Therapeutics (ONCE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7%
by Zacks Equity Research
Spark Therapeutics, Inc. (ONCE) shares rose above 5% in the last trading session.
Implied Volatility Surging for Spark Therapeutics (ONCE) Stock Options
by Zacks Equity Research
Investors in Spark Therapeutics, Inc. (ONCE) need to pay close attention to the stock based on moves in the options market lately.
Company News for January 05, 2017
by Zacks Equity Research
Companies In The News are: ONCE,CCL,SHAK,AMZN,CC
Spark Therapeutics Gets $15M Milestone Payment from Pfizer
by Zacks Equity Research
Spark Therapeutics (ONCE) received a $15 million milestone payment from partner Pfizer Inc. (PFE) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.